Concurrent Session 6A - Harm Reduction 1.0
Tracks
Track 1
Friday, November 1, 2024 |
1:10 PM - 2:40 PM |
Royal Theatre |
Details
Chair: John Gobeil, AIVL
Speaker
Dr Phillip Read
Director, Sexual Health And Bbv Services
South Eastern Sydney LHD
Sustaining take home naloxone (THN) since 2012: A review of THN provision between 2020-2023 from the Kirketon Road Centre, a primary healthcare setting in Kings Cross, Sydney
1:10 PM - 1:20 PMBiography
Dr Phill Read is the Director of Sexual Health and Blood Borne Virus Services in SESLHD. He is a sexual health physician who’s clinical work is conducted at the Kirketon Road Centre in Kings Cross, Sydney.
Ms Emma Kill
Ceo
QUIVAA
Voices of Lived Experience: The making of a comprehensive harm reduction environment from the expertise of overdose survivors
1:20 PM - 1:30 PMBiography
As CEO of QuIVAA, Qld’s peer-based drug-user organisation, Emma provides advocacy and tailored services supporting the PWUD community. Her social work background delivering therapeutic AOD services, alongside her commitment to the human rights of PWUD has seen her advocate for systemic reforms.
Professor Paul Dietze
Co_director, Disease Elimination Program
Burnet Institute
Individual-level harm reduction intervention coverage among people in Australia who inject drugs
1:30 PM - 1:40 PMBiography
Professor Paul Dietze has more than 20 years' in the alcohol and other drug field. His work has established internationally innovative surveillance systems and applied research designs that break new ground in the public health research into alcohol and other drug use and related harms in Australia.
Prof. Simon Lenton
Professor & Director
NDRI, Curtin University
Policy and practice diffusion and development in wider availability of naloxone in Australia 1999-2023 – substantial progress but more work to be done.
1:40 PM - 1:50 PMBiography
Professor Simon Lenton is the Director at the National Drug Research Institute and works as a Clinical Psychologist in private practice. He has been researching and writing on drug policy since 1994.
Miss Alice Pierce
Director Of External Engagement And Advocacy
NSW Users And Aids Association
Evaluation of an innovative online postal take-home naloxone service
1:50 PM - 2:00 PMBiography
Alice Pierce identifies as having living experience of drug use and is the Director of Programs at NUAA, leading peer workforce development, policy and advocacy, research, communications, and training initiatives. With a Bachelor of Arts with Honours and a Master of Laws (including a University Medal. Drawing on their own experience of drug use, Alice is passionate about community-driven harm reduction efforts that centre those with lived and living expertise.
Dr Erin Lalor
Chief Executive Officer
Alcohol and Drug Foundation
Strategies to reduce AOD-related harms among older adults
2:00 PM - 2:10 PMBiography
Dr Erin Lalor, PhD was appointed Chief Executive Officer of the Alcohol and Drug Foundation in 2017. Erin has over 20 years of leadership experience in the health sector, working in clinical, academic and executive roles, and was previously CEO of the National Stroke Foundation.
Dr Peter Gates
Postgraduate Research Fellow
NDARC
Defining approaches and research evidence around community action to reduce AOD harms
2:10 PM - 2:20 PMBiography
Dr Peter Gates has an extensive career with the National Drug and Alcohol Research Centre, starting in August 2002.
Peter leads the communities stream of the SUSTAIN program, which aims to identify communities with AoD harms, support the implementation of best-evidence AoD strategies, and evaluate the impact of these strategies.
Dr Rowan Ogeil
Senior Research Fellow, Monash University
Eastern Health
Ambulance data: crucial for capturing ‘hot-spots’ of pre-hospital AOD-related harms
2:15 PM - 2:25 PMBiography
Dr Ryan Baldwin
Research Fellow
Eastern Health
Ambulance data: crucial for capturing ‘hot-spots’ of pre-hospital AOD-related harms"
2:20 PM - 2:30 PMBiography
APSAD 2024
Session Q&A
2:30 PM - 2:40 PMBiography
Chair
John Gobeil
CEO
AIVL